Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence SAD Prior Auth Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy ORPTCOTH042

    Miscellaneous Products — Self‑Administered Drugs (SAD) Prior Authorization and Medical Administration Criteria

    Customize your policy alerts

    Sign up for Providence Health Plan Policy ORPTCOTH042 alerts

    Get alerted when Policy ORPTCOTH042 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, medical necessity, coding, and monitoring requirements for medications identified as self‑administered drugs (SADs) under Providence Health Plan, affecting Commercial and Medicaid members and providers requesting healthcare professional administration.

    Policy Summary
    PayerProvidence Health Plan
    PolicyMiscellaneous Products — Self‑Administered Drugs (SAD) Prior Authorization and Medical Administration Criteria
    Policy CodePolicy ORPTCOTH042
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when requesting healthcare professional administration of a medication listed in Table 1 and document chart notes supporting medical necessity (e.g., recent anaphylaxis, allergic reaction, inability to self-administer, or diagnosed needle phobia).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    60 daysInitial monitoring
    90 daysExtended example
    1 yearAuth duration
    Commercial, MedicaidApplies to
    Table 1Drug list
    Pharmacy Benefit OnlyPharmacy-only flag

    Coverage and Medical Necessity Criteria

    Medical Necessity for Provider Administration

    Provider administration may be considered medically necessary when ALL of the following apply as documented in chart notes:

    Provider administration criteria: 1) Relevant chart notes document medical rationale for requiring healthcare professional administration; AND 2) ONE of the following: history of anaphylaxis in the past 5 years requiring epinephrine or hospitalization; history of allergic reaction to the requested medication; documentation that the patient has a condition preventing self-administration (a: mental health/cognitive changes requiring increased level of care; b: physical conditions or dexterity issues that impede safe administration); inability to recognize or act on anaphylaxis; OR needle-phobia diagnosed by a mental health provider consistent with DSM criteria (general fear of needles excluded).

    Must be supported by chart documentation

    Initial Office-based Monitoring/Transition

    Coverage for initiation under the medical benefit:

    Transition monitoring: Upon initiation or approval for a SAD, the first 60 days will be covered at a provider's office to allow monitoring, patient training, and determination of suitability for self-administration; extended monitoring beyond 60 days is allowed per manufacturer labeling (example: Xolair® = 90 days).60 days standard; 90 days for specified drugs

    Continuation of provider administration after transition requires meeting medical necessity criteria

    Applicability and benefit assignment

    Coverage and applicability per Table 1

    SAD listing requirements: Medication must be listed in Table 1 with an HCPCS mapping to be governed by this policy.

    Table 1 entries indicate whether product is pharmacy-benefit-only or has medical transition availability

    Pharmacy Benefit Only: If 'Pharmacy Benefit Only' is marked, the medication will always start under the pharmacy benefit and is not subject to SAD policy exception requirements.

    These products are initiated via pharmacy benefit and are not eligible for provider-administration exceptions

    Medical Transition Available: If 'Medical Transition Available' is marked, initial administration may be required under the medical benefit for a 60- or 90-day transition period to monitor adverse reactions and provide patient training prior to continued provider administration.60- or 90-day

    Example: Xolair noted for 90-day

    None specified.

    Medications flagged as Pharmacy Benefit Only in Table 1 will always start under the pharmacy benefit and are not eligible for exceptions under this Self‑Administered Drugs (SAD) policy. These products should be initiated and billed through the pharmacy benefit rather than requested as provider‑administered under the SAD medical‑benefit pathway.

    Table 1 entries include field flags that identify benefit assignment and transition availability. Per the HCPCS mapping fields, field 3 = Medical Transition Available and field 4 = Pharmacy Benefit Only, which indicate whether a product may require an initial monitored medical administration period or will always begin under the pharmacy benefit.

    Subcutaneously administered drugs that appear on the Usually Self‑Administered list will be denied as a benefit exclusion when provider administration is requested without meeting the policy’s medical necessity requirements. Claims for J/Q codes that have multiple routes and are marked with an asterisk in Table 1 must include the correct route modifier (JA for intravenous or JB for subcutaneous); failure to apply the appropriate modifier may result in denial.

    Coding, Modifiers, and Code Mappings

    Route of Administration ModifiersModifier
    JAModifier required when the drug's HCPCS J/Q code refers to the intravenous route
    JBModifier required when the drug's HCPCS J/Q code refers to the subcutaneous route
    SAD HCPCS mappings (as listed in Table 1)HCPCS
    J3490Tymlos; Abaloparatide; Strensiq; Dawnzera; Donidalorsen; many other entries (used as unclassified drug J-code for multiple brands listed)
    J0129Orencia Clickjet (Abatacept)
    J0139Humira (Adalimumab)
    Q5144Idacio (Adalimumab-aacf)
    Q5141Yuflyma (Adalimumab-aaty)
    J3590Multiple brands listed under J3590 (e.g., Hyrimoz, Yusimry, Amjevita, Hadlima, Trulicity, Dupixent, many others)
    Q5143Cyltezo (Adalimumab-adbm)
    Q5145Abrilada (Adalimumab-afzb)
    Q5140Hulio (Adalimumab-fkjp)
    Q5142Simlandi (Adalimumab-ryvk)
    1–10 of 36
    1/4
    HCPCS/J codes (partial list from document)HCPCS
    J3590Enspryng; Satralizumab-mwge; Cosentyx (subq); Secukinumab; Winrevair; Sotatercept-csrk; Adbry; Tralokinumab; (others listed across chunks)
    J3490Ozempic (Semaglutide); Wegovy (Semaglutide); Gattex (Teduglutide); Mounjaro (Tirzepatide); Zepbound (Tirzepatide); Zilbrysq (Zilucoplan)
    J2940Protropin; Somatrem
    J1747*Spevigo; Spesolimab-sbzo
    J3030Imitrex; Sumatriptan succinate
    J3110Forteo; Teriparatide
    J2356Tezspire; Tezepelumab-ekko
    J3357Stelara; Ustekinumab
    Q/C codes (partial list from document)HCPCS
    Q5135*Tyenne; Tocilizumab-aazg
    Q9999Otulfi; Ustekinumab-aauz
    Q9998*Selarsdi; Ustekinumab-aekn
    Q5137Wezlana; Ustekinumab-auub
    C9399Yesintek; Ustekinumab-kfce
    Q5100Ustekinumab-kfce and related Ustekinumab products
    Q5098Ustekinumab-kfce, Ustekinumab-srlf
    Q5099*Imuldosa/SteQeyma; Ustekinumab-srlf, Ustekinumab-stba
    Q9996Pyzchiva; Ustekinumab-ttwe
    Initial monitored administration period
    Standard initial monitored administration periodFirst 60 days of therapy are covered at a provider's office for monitoring and patient training
    Extended monitoring exampleManufacturer-labeled exceptions allowed; example: Xolair® (omalizumab) initiation allowed 90 days administration and monitoring at provider's office
    Purpose of monitoring periodAllows monitoring for adverse reactions (including anaphylaxis), patient training in administration technique, and assessment of suitability for home self-administration
    Medical transition monitoring period
    Medical transition period lengthMedications marked as 'Medical Transition Available' may require a 60-day transition period; select drugs (e.g., Xolair®) may require 90 days

    Provider Requirements, Prior Authorization, and Billing Guidance

    Prior Authorization

    Prior authorization required for listed SADs

    Prior authorization is required when a provider requests healthcare-professional administration of any medication listed in Table 1; approvals for provider administration are for an initial monitored transition period (typically 60 days, or 90 days for specified drugs such as Xolair®).

    • Authorization approval authorizes provider administration for the initial monitoring/transition period only (standard = 60 days; Xolair example = 90 days).
    Prior Authorization

    Table 1 entries subject to Pharmacy Prior Authorization ORPTCOTH042

    Medications shown in Table 1 are governed by the Pharmacy Prior Authorization Policy ORPTCOTH042; Table 1 entries indicate the HCPCS code, brand/generic name, whether a medical-benefit transition is available, and whether the product is pharmacy-benefit-only.

    • If 'Pharmacy Benefit Only' is marked in Table 1 the medication will always start under the pharmacy benefit and is not eligible for SAD policy exception requests.

    Initiation and Transition Therapy Rules

    Initial Therapy Monitoring

    Initiation/transition rules for SADs

    Initial provider administration: First 60 days of therapy are covered at a provider office for monitoring and patient training; exceptions for specific drugs per manufacturer labeling (e.g., Xolair® 90 days).60 days

    Table 1 identifies medications subject to this transition period

    Initial benefit assignment

    Initial benefit assignment guidance

    Pharmacy-start drugs: Drugs marked as 'Pharmacy Benefit Only' start under the pharmacy benefit from initiation and are not subject to SAD exception requests for medical administration.

    These are not eligible for provider-administration exceptions

    Continuation and Reauthorization Requirements

    Authorization Duration

    Duration of authorization

    Reauthorization: Authorization and reauthorization for coverage under the medical benefit will be approved for one year.1 year

    Continuation after medical transition

    Continuation requirements tied to benefit and transition flags

    Continuation after transition: Continuation of provider-administration after the medical transition period is subject to the medical necessity criteria outlined in this policy; ongoing provider administration must be justified by chart-documented rationale meeting the criteria for provider administration.

    Refer to Table 1 flags to determine whether the product is eligible for medical transition or is pharmacy-benefit-only

    Step Therapy and New Indication Reviews

    SituationPolicy Action / Review Process
    Request for a new FDA-approved indication within the prior 6 monthsReviewed under the New Drug and/or Indication Awaiting P&T Review prior authorization process (ORPTCOPS047). Requests may be evaluated for safety, effectiveness, and inclusion on policy before coverage determination.
    Request for a non–FDA-approved (off‑label) indicationRequires that the proposed indication is listed in AHFS, Drugdex, or NCCN and will be evaluated based on prescriber medical rationale, formulary alternatives, available evidence, and determination if the use is experimental/investigational.
    ScenarioPolicy requirement / Benefit assignment
    Medication listed with 'Medical Transition Available' in Table 1Initial administration may be required under the medical benefit for a defined transition period (typically 60 days; 90 days for specified drugs such as Xolair) to allow monitoring and patient training. Continuation of provider administration after transition requires meeting medical necessity criteria.
    Medication marked 'Pharmacy Benefit Only' in Table 1Will always start under the pharmacy benefit and is not eligible for SAD policy exceptions to initiate provider (medical benefit) administration.

    Quantity Limits and Related References

    See applicable clinical policy/formulary
    Quantity limits referenceSee applicable clinical policy and/or formulary documents for quantity limits and related restrictions
    New FDA indicationsRequests for indications approved within the previous 6 months may be reviewed under the New Drug/Indication Awaiting P&T policy
    Off‑label indicationsRequests for off‑label use require citation in AHFS, Drugdex, or NCCN and prescriber rationale

    Site of Care and Initial Administration Location

    Step Therapy

    Cover initial 60 days (or manufacturer period) at provider office for initiation

    The first 60 days (or manufacturer‑specified period) of therapy for SADs must be covered at a provider's office to allow monitoring, patient training in administration technique, and recognition of anaphylaxis; extended monitoring beyond 60 days is permitted when recommended by the manufacturer (example: Xolair® = 90 days).

    • This office‑based initiation requirement applies upon initiation or approval for a SAD listed drug.
    Step Therapy

    Initial provider administration may occur in infusion center, office, or home for flagged drugs

    Some medications flagged in Table 1 as having a medical transition available require initial provider administration (medical benefit) in settings such as infusion center, office, or home to permit monitoring and patient training; products marked 'Pharmacy Benefit Only' are initiated via pharmacy and are not eligible for these SAD exceptions.

    • Settings for initial administration include infusion center, office, or home per the product's transition designation.

    Biosimilar and Specific Drug Notes

    Billing Rule

    HCPCS/Q/C code mappings provided for ustekinumab products (no interchange preference stated)

    Ustekinumab and its biosimilars are mapped to various Q/C/HCPCS codes in Table 1; the policy provides the code mappings but does not state a biosimilar preference or interchange rule.

    • Multiple Q and HCPCS codes (for example Q5100, Q5098, Q5099*, Q9996, J3357) are mapped to branded and biosimilar ustekinumab products in Table 1.

    Background and Scope

    Self‑administered drugs (SADs) are medications identified as appropriate for patient or caregiver administration without medical supervision. This policy governs requests for healthcare professional administration of SADs, establishes documentation and prior authorization requirements, and defines initial monitored administration under the medical benefit when listed in Table 1. To balance safety and access, the policy typically requires the first 60 days of therapy to be covered at a provider’s office for monitoring and patient training, with some drugs (for example, Xolair®) identified in Table 1 for an extended 90‑day transition when manufacturer labeling indicates.

    Definitions and Flags

    Self-administered drugs
    DefinitionMedications identified as medically appropriate for administration by a patient or caregiver, safely and effectively, without medical supervision
    ImplicationDrugs on the SAD list are expected to be self‑administered absent documented medical necessity for provider administration
    Training relevancePolicy requires provider monitoring/training period upon initiation to confirm suitability for home self‑administration
    Route of administration
    DefinitionThe process by which a medication enters the body (for example: oral, intravenous, subcutaneous)
    Coding impactRoute of administration determines required modifiers (e.g., JA for intravenous, JB for subcutaneous) when billing provider administration

    Additional Provider Notes

    Denial Risk

    Coding-related denial risk: missing JA/JB modifiers

    Repeat: claims for Table 1 drugs marked with an asterisk billed without JA/JB modifiers may be denied; ensure the correct route modifier is applied for J/Q codes with multiple routes of administration.

    • Missing or incorrect modifiers on J/Q codes is a common cause for claim denials under this policy.
    Policy Summary
    PayerProvidence Health Plan
    PolicyMiscellaneous Products — Self‑Administered Drugs (SAD) Prior Authorization and Medical Administration Criteria
    Policy CodePolicy ORPTCOTH042
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when requesting healthcare professional administration of a medication listed in Table 1 and document chart notes supporting medical necessity (e.g., recent anaphylaxis, allergic reaction, inability to self-administer, or diagnosed needle phobia).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding, Modifiers, and Code MappingsProvider Requirements, Prior Authorization, and Billing GuidanceInitiation and Transition Therapy RulesContinuation and Reauthorization RequirementsStep Therapy and New Indication ReviewsQuantity Limits and Related ReferencesSite of Care and Initial Administration LocationBiosimilar and Specific Drug NotesBackground and ScopeDefinitions and FlagsAdditional Provider Notes
    When transition appliesApplies to medications listed in Table 1 with the 'Medical Transition Available' designation
    Post-transition continuationContinuation of provider administration after the transition period requires meeting the policy's medical necessity criteria
    Billing Rule

    Use listed HCPCS/J/Q mappings from Table 1 when submitting claims/requests

    Use the HCPCS, J, and Q/C code mappings listed in Table 1 when submitting prior authorization requests or claims for provider administration of SADs; specific codes in the table map to brand and generic drug names and flags.

    • Examples: J3590 → multiple listed brands (e.g., Enspryng, Cosentyx); J3490 → Ozempic/Wegovy/Mounjaro; Q5135* and other Q/C codes map to Ustekinumab biosimilars.
    • Follow the exact HCPCS/J/Q/C code listed in Table 1 for the product being requested.
    Step Therapy

    New or off‑label indication requests require New Drug/Indication review

    Requests for indications approved by the FDA within the previous six months, or for non‑FDA (off‑label) indications, must be reviewed under the New Drug/Indication awaiting P&T procedures and require supporting references and prescriber rationale.

    • New FDA indications (≤6 months) are reviewed using the New Drug and/or Indication Awaiting P&T Review (ORPTCOPS047).
    • Off‑label indications must be listed in AHFS, Drugdex, or NCCN and be supported by the prescriber's medical rationale and evidence.
    Step Therapy

    Initiate certain SADs under the medical benefit for 60–90 day monitoring

    Some medications listed in Table 1 that are marked 'Medical Transition Available' must be initiated under the medical benefit for a defined monitoring/training period (typically 60 days; certain products such as Xolair® require 90 days).

    • Continuation of provider administration after the transition period remains subject to the medical necessity criteria in this policy.
    Note
    Documentation Required

    Provide chart notes documenting medical rationale for provider administration

    Include relevant chart notes documenting the medical rationale for provider administration; documentation must support one of the policy criteria (e.g., recent anaphylaxis requiring epinephrine or hospitalization, allergic reaction to the requested medication, inability to safely self-administer due to cognitive or physical impairment, inability to recognize or act on anaphylaxis, or diagnosed needle phobia).

    • Chart documentation must explicitly support the chosen rationale and timeframe (e.g., history of anaphylaxis within past 5 years).
    Documentation Required

    Include package inserts and external references to support requests

    Use the policy's referenced supporting resources to substantiate medical necessity determinations; the document specifically cites relevant package inserts, the Noridian SADs policy, and the CMS Medicare Benefit Policy Manual.

    • Referenced resources: package inserts; Noridian Self‑Administered Drugs policy; CMS Medicare Benefit Policy Manual Chapter 15.
    Note

    Consult Table 1 for medications, codes, and benefit flags

    Refer to Table 1 for the complete list of medications covered under the Miscellaneous Products SAD scope and to determine the HCPCS mapping, Medical Transition Available flag, and Pharmacy Benefit Only flag for each product.

    • Table 1 identifies whether a medication is eligible for medical-benefit transition or is Pharmacy Benefit Only.
    Denial Risk

    Billed J/Q codes with multiple routes must include JA or JB modifier or claim will be denied

    Claims for drugs marked with an asterisk (*) in Table 1 that have multiple routes must be billed with the required route modifier (JA for intravenous or JB for subcutaneous); claims submitted without the appropriate JA/JB modifier will be denied.

    • JA = Intravenous administration; JB = Subcutaneous administration.
    • Subcutaneously administered drugs listed as Usually Self‑Administered will be denied as a benefit exclusion absent meeting medical necessity criteria.
    Denial Risk

    Provider administration requests for self‑administered products are reviewed for medical necessity; pharmacy‑only items are ineligible

    Requests for healthcare (provider) administration of medications labeled for patient self‑administration are subject to medical necessity review; medications that are Pharmacy Benefit Only will not be eligible for SAD policy exceptions and will start under the pharmacy benefit.

    • Any medication labeled for patient self‑administration in Table 1 may be reviewed for medical necessity if provider administration is requested.
    • Pharmacy‑benefit‑only products are not eligible for exception to start under medical benefit.
    Note

    Follow Table 1, coding, prior authorization and documentation requirements (no other explicit actions listed)

    No additional explicit authorization actions or alternate denial procedures are specified beyond those in Table 1 and the policy language; follow Table 1 mappings, prior authorization requirements, modifier rules, and documentation guidance as stated.

    • Table 1 and policy sections provide the actionable requirements for authorization, coding, and documentation.
    Medical-transition drugs: Drugs with 'Medical Transition Available' may require initial administration under the medical benefit for a defined transition period (typically 60 days, or 90 days for specific products) for monitoring and patient training before determining suitability for self-administration.60- or 90-day

    Continuation after transition is subject to medical necessity criteria

    Clinical relevanceRoute influences monitoring needs and whether therapy is appropriate for self‑administration
    Medical Transition Available
    DefinitionFlag indicating a medication may require initiation under the medical benefit for a defined transition period (typically 60 days; selected drugs may be 90 days) to monitor adverse reactions and provide patient training
    ApplicationMedications with this flag are listed in Table 1 under the 'Medical Transition Available' column
    ContinuationAfter the transition period, continued provider administration is subject to medical necessity criteria in the policy
    Pharmacy Benefit Only
    DefinitionFlag indicating medications that will always start under the pharmacy benefit and are not eligible for SAD policy exceptions for initial provider administration
    Table 1 identificationThese products are marked in Table 1 under the 'Pharmacy Benefit Only' column
    Implication for requestsRequests for healthcare professional administration of pharmacy‑benefit‑only products will not be eligible for SAD policy exceptions
    HCPCS mapping fields
    Field 1 — Brand NameHCPCS mapping field 1 contains the product's brand name as listed in Table 1
    Field 2 — Generic NameHCPCS mapping field 2 contains the product's generic name
    Field 3 — Medical Transition AvailableHCPCS mapping field 3 indicates whether a medical‑benefit transition period is available (marked 'X' when present)
    Field 4 — Pharmacy Benefit OnlyHCPCS mapping field 4 indicates whether the product is pharmacy‑benefit‑only (marked 'X' when present)